Ubicación del inventario
- New Jersey, USA
- Czech Republic, EU
- Mumbai, India
* Sujeto a disponibilidad
Documentation
Incluye: HPLC, MASS/LC-MS, RMN de 1H, FT-IR, potencia, informe de elucidación estructural (SER) y datos analíticos adicionales según el producto.
2-Cyno Ethisterone
● En Stock
| Número de catálogo: | VE0025317 |
|---|---|
| N.º CAS: | N/A |
| Fórmula mol.:: | C22H27NO2 |
| Peso mol.:: | 337.46 g/mol |
Información adicional sobre el 2-Cyno Ethisterone
Fármaco de origen
NorethisteroneNombre IUPAC
(10R, 13S, 17R)-17-ethynyl-17-hydroxy-10, 13-dimethyl-3-oxo-2, 3, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17-tetradecahydro-1H-cyclopenta[a]phenanthrene-2-carbonitrileSinónimos farmacopeicos
N/AOtros sinónimos
N/ASMILES
N#CC1C(C=C(CCC2C3CC[C@@]4(C)C2CC[C@]4(C#C)O)[C@]3(C)C1)=OInChI
InChI=1S/C22H27NO2/c1-4-22(25)10-8-18-16-6-5-15-11-19(24)14(13-23)12-20(15, 2)17(16)7-9-21(18, 22)3/h1, 11, 14, 16-18, 25H, 5-10, 12H2, 2-3H3/t14?, 16?, 17?, 18?, 20-, 21-, 22-/m0/s1Descripción
2-Cyno Ethisterone impurity is a structurally related byproduct arising from incomplete reduction or inadvertent cyanomethylation during steroidal ethisterone synthesis. It presents specific analytical challenges due to close retention characteristics and similar mass spectral fragments to the parent API | necessitating orthogonal methods such as reversed phase HPLC with UV and LC-MS confirmation | high resolution mass spectrometry and 1H and 13C NMR for unambiguous identification. Risk assessment should address formation pathways | stability under forced degradation | solubility and polymorphism effects | and potential impact on pharmacopoeial specifications. A robust control strategy including process optimization | in-process monitoring and validated impurity limits aligned with ICH guidance is recommended.
Solicitar cotización
"*" señala los campos obligatorios